<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163050">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01812096</url>
  </required_header>
  <id_info>
    <org_study_id>chengchengfu</org_study_id>
    <nct_id>NCT01812096</nct_id>
  </id_info>
  <brief_title>Improved PAD Regimen In Multiple Myeloma</brief_title>
  <acronym>MM</acronym>
  <official_title>Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous injection is the standard administration route of bortezomib; however,
      subcutaneous administration is an important alternative. We want to compared the effi cacy
      and safety of subcutaneous versus intravenous bortezomib at the approved 1â€¢3 mg/m2 dose and
      twice per week,on days1, 4, 8 and 11 of 21-day cycles, schedule in patients with multiple
      myeloma. At the same time we adjust the dose of dexamethasone at 10mg and twice everyday, on
      days 1, 2, 4, 5, 8, 9, 11 and 12.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>overall survival rates</measure>
    <time_frame>three years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>three years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Myeloma Proved by Laboratory Tests</condition>
  <arm_group>
    <arm_group_label>Subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAD regimen with subcutaneous bortezomib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PAD regimen with intravenous bortezomib</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Subcutaneous  bortezomib</intervention_name>
    <arm_group_label>Subcutaneous</arm_group_label>
    <other_name>the methods of use bortezomib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravenous bortezomib</intervention_name>
    <arm_group_label>Intravenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be Multiple Myeloma Proved by Laboratory Tests

          -  Must have the ability to observe the efficacy and events

          -  Patient must have the ability to understand and willingness to provide written
             informed consent in the study and any related procedures being performed

        Exclusion Criteria:

          -  If have uncontrolled intercurrent illness including ongoing or active infection,heart
             failure,unstable angina pectoris,or psychiatric illness/social situations that study
             requirements

          -  If have severe side-effects on bortezomib
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fu chengcheng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital,Soochow University</affiliation>
  </overall_official>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 13, 2013</lastchanged_date>
  <firstreceived_date>March 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>bortezomib</keyword>
  <keyword>Subcutaneous</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
